Acelyrin, Inc. (NASDAQ:SLRN) is a promising biopharmaceutical company specializing in autoimmune disease treatments. Despite setbacks, recent trial successes and strong financials position SLRN as one of the best new penny stocks to buy, with analysts bullish on its growth potential.